CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treatment
/PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL) today announced the presentation of data affirming the long-term durability and safety of...